Inhibikase Therapeutics (IKT) Stock Forecast, Price Target & Predictions
IKT Stock Forecast
Inhibikase Therapeutics stock forecast is as follows: an average price target of $6.50 (represents a 103.13% upside from IKT’s last price of $3.20) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
IKT Price Target
The average price target for Inhibikase Therapeutics (IKT) is $6.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $5.00. This represents a potential 103.13% upside from IKT's last price of $3.20.
IKT Analyst Ratings
According to 3 Wall Street analysts, Inhibikase Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for IKT stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Inhibikase Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 08, 2024 | Dennis Ding | Jefferies | $8.00 | $2.78 | 187.77% | 150.00% |
| Oct 11, 2024 | Edward White | H.C. Wainwright | $5.00 | $1.42 | 252.09% | 56.25% |
The latest Inhibikase Therapeutics stock forecast, released on Nov 08, 2024 by Dennis Ding from Jefferies, set a price target of $8.00, which represents a 187.77% increase from the stock price at the time of the forecast ($2.78), and a 150.00% increase from IKT last price ($3.20).
Inhibikase Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 2 |
| Avg Price Target | - | $6.50 | $6.50 |
| Last Closing Price | $3.20 | $3.20 | $3.20 |
| Upside/Downside | -100.00% | 103.13% | 103.13% |
In the current month, the average price target of Inhibikase Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Inhibikase Therapeutics's last price of $3.20. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 08, 2024 | Jefferies | Buy | Initialise | |
| Oct 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 21, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Nov 16, 2022 | JonesTrading | Hold | Downgrade |
Inhibikase Therapeutics's last stock rating was published by Jefferies on Nov 08, 2024. The company Initialise its IKT rating from "null" to "Buy".
Inhibikase Therapeutics Financial Forecast
Inhibikase Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $7.29K | $6.55K | - | $1.94K | $328.46K | $1.36M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $200.00K | $300.00K | $300.00K | $300.00K | $200.00K | $300.00K |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | $200.00K | $300.00K | $300.00K | $300.00K | $200.00K | $300.00K |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $200.00K | $300.00K | $300.00K | $300.00K | $200.00K | $300.00K |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.04% | 0.02% | - | 0.01% | 1.64% | 4.54% |
Inhibikase Therapeutics's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. IKT's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $7.29K (Sep 22).
Inhibikase Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-4.49M | $-4.64M | $-4.64M | $-5.04M | $-4.47M | $-2.63M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $-200.00K | $-300.00K | $-4.37M | $-300.00K | $-3.19M | $-300.00K |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | $-200.00K | $-300.00K | $-3.49M | $-300.00K | $-2.56M | $-300.00K |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $-200.00K | $-300.00K | $-5.24M | $-300.00K | $-3.83M | $-300.00K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 22.47% | 15.47% | 1.06% | 16.80% | 1.40% | 8.76% |
undefined analysts predict IKT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Inhibikase Therapeutics's previous annual EBITDA (undefined) of $NaN.
Inhibikase Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-4.46M | $-4.64M | $-4.64M | $-5.04M | $-4.47M | $-2.64M |
| Avg Forecast | $-1.87M | $-1.07M | $-1.07M | $-977.08K | $-1.33M | $-1.24M | $-1.07M | $-977.08K | $-769.83K | $-4.26M | $-5.05M | $-8.14M | $-8.59M | $-4.37M | $-7.69M | $-3.19M | $-17.18M |
| High Forecast | $-1.87M | $-1.07M | $-1.07M | $-977.08K | $-1.33M | $-1.24M | $-1.07M | $-977.08K | $-692.84K | $-4.26M | $-5.05M | $-8.14M | $-8.59M | $-3.49M | $-7.69M | $-2.55M | $-17.18M |
| Low Forecast | $-1.87M | $-1.07M | $-1.07M | $-977.08K | $-1.33M | $-1.24M | $-1.07M | $-977.08K | $-769.83K | $-4.26M | $-5.05M | $-8.14M | $-8.59M | $-5.24M | $-7.69M | $-3.83M | $-17.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.55% | 0.54% | 1.06% | 0.66% | 1.40% | 0.15% |
Inhibikase Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IKT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Inhibikase Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $1.54M | $1.66M | $1.67M | $1.65M | $1.64M | $1.61M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $3.43M | $5.15M | $5.15M | $5.15M | $3.43M | $5.15M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | $3.43M | $5.15M | $5.15M | $5.15M | $3.43M | $5.15M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $3.43M | $5.15M | $5.15M | $5.15M | $3.43M | $5.15M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.45% | 0.32% | 0.32% | 0.32% | 0.48% | 0.31% |
Inhibikase Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to IKT last annual SG&A of $1.54M (Sep 22).
Inhibikase Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.18 | $-0.18 | $-0.18 | $-0.20 | $-0.18 | $-0.22 |
| Avg Forecast | $-0.21 | $-0.12 | $-0.12 | $-0.11 | $-0.15 | $-0.14 | $-0.12 | $-0.11 | $-0.09 | $-0.48 | $-0.67 | $-1.08 | $-1.14 | $-1.02 | $-1.02 | $-0.84 | $-2.28 |
| High Forecast | $-0.21 | $-0.12 | $-0.12 | $-0.11 | $-0.15 | $-0.14 | $-0.12 | $-0.11 | $-0.08 | $-0.48 | $-0.67 | $-1.08 | $-1.14 | $-1.02 | $-1.02 | $-0.84 | $-2.28 |
| Low Forecast | $-0.21 | $-0.12 | $-0.12 | $-0.11 | $-0.15 | $-0.14 | $-0.12 | $-0.11 | $-0.09 | $-0.48 | $-0.67 | $-1.08 | $-1.14 | $-1.02 | $-1.02 | $-0.84 | $-2.28 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.17% | 0.16% | 0.18% | 0.20% | 0.21% | 0.10% |
According to undefined Wall Street analysts, Inhibikase Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IKT previous annual EPS of $NaN (undefined).
Inhibikase Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LGVN | Longeveron | $1.78 | $10.00 | 461.80% | Buy |
| MIST | Milestone Pharmaceuticals | $1.82 | $10.00 | 449.45% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| SCPH | scPharmaceuticals | $3.25 | $13.00 | 300.00% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| ANTX | AN2 Therapeutics | $1.34 | $5.00 | 273.13% | Buy |
| IKT | Inhibikase Therapeutics | $3.97 | $6.50 | 63.73% | Buy |
| DMAC | DiaMedica Therapeutics | $5.20 | $8.50 | 63.46% | Buy |
| MCRB | Seres Therapeutics | $0.88 | $1.25 | 42.05% | Buy |